摘要
Cancer metastasis, resistance to treatment, and relapse are major issues faced by patients with cancer. Research on cancer relapse is ongoing. Tumors are becoming resistant to traditional chemotherapy, targeted therapy, and immunotherapy. The problem resides at the cancer cell receptors. Receptors are small pockets that can sometimes be blocked with small targeted molecules, sensitive to traditional chemotherapy, or more complex ones that require checkpoint inhibitor antibodies in immune-oncology treatment. Each scenario has its own implications for the clinical benefit of patients. This short communication examines the various cancer settings and their relation to drug sensitivities of receptors with the aim of finding solutions to the problem of distinguishing between friends and foes in novel cancer treatments.
延伸閱讀
- Chang, D. S., Kuo, T. H., Hwang, S. L., & Howng, S. L. (1997). The Familial Occurrence of Brain Tumors. The Kaohsiung Journal of Medical Sciences, 13(4), 268-271. https://doi.org/10.6452/KJMS.199704.0268
- 徐偉勛、李日翔、林家齊、楊志新（2014）。Novel Targets for Lung Cancer。台灣醫學，18(6)，688-694。https://doi.org/10.6320/FJM.2014.18(6).09
- 葉坤輝（2003）。Targeted Cancer Therapy: An Overview。台灣醫學，7(2)，207-211。https://doi.org/10.6320/FJM.2003.7(2).08
- 胡文郁、陳瑞儀（2017）。The Good Dying of Patients with Tumor。腫瘤護理雜誌，17()，5-16。https://doi.org/10.3966/168395442017101703001
- 郭蓁蓁、王秀紅、周汎澔（2018）。Cancer-Related Fatigue: A Concept Analysis。腫瘤護理雜誌，18(1)，91-105。https://doi.org/10.3966/168395442018061801008